<DOC>
	<DOCNO>NCT01201239</DOCNO>
	<brief_summary>To assess safety , tolerability efficacy Raltegravir ( RAL ) combine antiretroviral drug treatment-experienced Chinese HIV-infected patient , include multi-drug resistant HIV-1 infection drug intolerance .</brief_summary>
	<brief_title>Efficacy Safety Raltegravir ( RAL ) Treatment-experienced HIV-1 Infected Adult Chinese Patients</brief_title>
	<detailed_description>An open , prospective , uncontrolled pilot study evaluate efficacy safety raltegravir treatment-experienced HIV-1 infect adult patient fail previous antiretroviral treatment due drug resistance drug intolerance . 1 . Patients Enrollment : HIV-infected patient age 18 fail previous antiretroviral treatment multi-drug resistant multi-drug intolerance eligible . And least 50 subject conclude trial . ⅰ ) The diagnostic criterion HIV/AIDS refer guideline diagnosis treatment HIV/AIDS China ( 2005 ) . ⅱ ) Treatment failure define follow : ( ) : HIV viral load decrease less 1 log copies/ml patient 8 week HAART , ( ii ) HIV viral load still detectable 6 month HAART ; ( iii ) reappearance detectable viral load HAART lead undetectable viral load . ⅲ ) The definition drug resistance base genotypic resistance test . ⅳ ) Drug intolerance involve serious antiretroviral drug relate adverse event , AZT relate bone marrow suppression , NVP EFV relate serious liver damage allergic reaction , d4T relate lactic acidosis , pancreatitis peripheral neuritis , etc . 2 . Patients enrol study sign consent form . 3 . Antiretroviral regimen subject : The patient enrol study accept treatment regimen RAL 400 mg twice daily plus OBT ( optimize background therapy ) , select basis patient 's antiretroviral treatment history , result available genotypic resistance test , previous current laboratory abnormality intolerance antiretroviral drug , shall , possible , contain two anti-retroviral drug fully active patient 's virus genotype . 4 . Data collection : For patient , detection HIV viral load CD4+ T lymphocyte count do screening , week 4 , 12 , 24 48 . The safety profile RAL monitor accord patient ' complaint result physical laboratory examination . Plasma HIV RNA viral load determine HIV-1 Quantiplex ( bDNA ) assay approve FDA . CD4+ T lymphocytes count flow cytometry . Any drug-related adverse event patient experience treatment record , nausea , vomit , abdominal pain , abodominal distension , diarrhea , fever , headache , dizzy , fatigue etc . Laboratory examination cover blood , urine stool routine , liver renal function , electrolytes , blood glucose , blood lipid , electrocardiogram etc . 5 . Endpoints study : The primary endpoint safety tolerability RAL 400 mg b.i.d . combination OBT , assess review accumulate safety data HIV-infected adult patient . The secondary endpoint antiretroviral activity RAL 400 mg b.i.d . combination OBT measure change week 24 viral load baseline , increase CD4+ T lymphocytes compare baseline proportion patient : viral load le 400 copies/ml ; viral load le 50 copies/ml ; reduction viral load baseline exceed 1.0 log10 copies/ml .</detailed_description>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>HIVinfected patient age 18 fail previous antiretroviral treatment multidrug resistant multidrug intolerance The patient age 18 65 year The patient serious opportunistic infection tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>raltegravir</keyword>
	<keyword>HIV-1</keyword>
	<keyword>drug resistance</keyword>
</DOC>